Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

IVL-DrugFluidic® can mass-produce high-quality, long-acting injectable drug microspheres, improving patient compliance and reducing side effects.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

Baricitinib significantly regrows hair in teens with severe alopecia areata.

Ritlecitinib is cost-effective for severe alopecia areata in Japan.

A 12-year-old girl's hair loss was linked to a rare genetic condition called ALX4-related frontonasal dysplasia.

Ritlecitinib was generally well tolerated in children with alopecia areata.

i-PRF and A-PRF show promise in promoting hair regrowth and improving scalp health in androgenetic alopecia.

Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.

5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.

A-PRF+ improves bone healing and stability in oral surgery.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Co-trimoxazole successfully treated a girl with multiple autoimmune symptoms.

AIRE-deficient rats developed severe autoimmune disease similar to APECED, useful for testing treatments.

Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

ACKR2 helps prevent skin scarring and hair loss by controlling inflammation.

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

New oral anticoagulants are safer and easier to use with new reversal agents for bleeding emergencies.

Cytarabine can cause multiple organ toxicities, especially neurotoxicity, but better research methods are needed to fully understand and predict these effects.

Hypaphorine from a fungus changes the internal structure of Eucalyptus root hairs, stopping their growth.

RU 58841 may treat acne, hair loss, and excessive hair growth.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

A new mutation in the XEDAR gene might cause a rare skin condition called hypohidrotic ectodermal dysplasia.

No effective treatment exists to stimulate hair growth in atrichia with papular lesions.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Reducing Zyxin may help treat hair loss.

A woman had a delayed allergic reaction to the blood thinner enoxaparin, treated with a steroid cream.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

Targeting amphiregulin may improve treatment for fibrosis and cancer.